Ketamine for the Treatment of Opioid Use Disorder and Depression

Depression Clinical Trial

Official title:

A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Ketamine for the Treatment of Concurrent Opioid Use Disorder and Major Depressive Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04177706
• Other study ID #: 00091292
• Secondary ID: K12DA031794
• Status: Completed
• Phase: Phase 2
• Start date: December 17, 2020
• Est. completion date: February 28, 2023

Study information

• Verified date: August 2023
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: February 28, 2023
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Between the ages of 18 to 65 years old.

2. Able to provide informed consent.

3. Meet DSM-5 criteria for Major Depressive Disorder, without psychotic features.

4. Score at least 20 on the Montgomery-Asberg Depression Rating Scale.

5. Fulfill a minimum of 4 of 11 current opioid use disorder criteria by DSM-5.

6. Have used opioids illicitly at least once in the past month.

7. Subjects must be on standard of care pharmacotherapy for OUD (buprenorphine) for at least one month.

8. Subjects taking other psychotropic medications (e.g. anti-depressants or non benzodiazepine anxiolytics) must be maintained on a stable dose for at least four weeks before study initiation.

9. Subjects must be considered to have treatment-refractory MDD as evidenced by failure or only partial response to treatment with at least two standard of care pharmacotherapy antidepressants.

10. Must consent to random assignment to intranasal ketamine or placebo control. Exclusion Criteria: They are considered an immediate suicide risk (by Columbia Suicide Severity Rating Scale of 4 or greater, a history of a suicide attempt in the past year, or by clinician judgment) or felt to be likely to require hospitalization during the course of the study.

2. They have a self-reported history of illicit ketamine use, or baseline urine drug testing positive for ketamine.

3. They are in acute opioid withdrawal (as evidenced by a score of 5 or above on the Clinician Opioid Withdrawal Scale). These subjects will be referred for clinical detoxification and pharmacotherapy induction. Subjects may be re-assessed for study eligibility after one month of treatment with a standard of care OUD pharmacotherapy.

4. Subjects who meet DSM-5 criteria for current bipolar disorder. 5. Subjects who meet DSM-5 criteria for current or history of psychotic spectrum disorders.

6. Women who are pregnant or nursing. 7. Subjects with current hypertension as defined by a systolic blood pressure (SBP) >140 mmHg or a diastolic blood pressure (DBP) >90 mmHg.

8. Subjects with a self-reported history of delirium for any cause. 9. A history of allergic or other adverse reaction to ketamine. 10. Clinically significant abnormal laboratory values, physical exam findings or self-reported medical conditions for which a transient increase in blood pressure could be significantly detrimental (e.g. glaucoma, brain aneurysms, cardiovascular disease, or end-stage renal disease).

11. Electrocardiogram (ECG) findings (obtained within thirty days prior to randomization) of tachycardia, prior myocardial infarction, myocardial ischemia, or aberrant conduction).

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Opioid Abuse
• Opioid-Related Disorders
• Opioid-use Disorder
• Substance-Related Disorders

Intervention

Drug:
• Ketamine Hydrochloride
Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
• Placebo
Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Medical University of South Carolina	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Individuals Completing Informed Consent	Primary outcomes will be 1) the percentage of individuals completing informed consent out of the number of individuals eligible on the initial screening.	Outcomes will be cumulatively assessed from the time that the first participant is screened through the time that the last participant is enrolled. Estimated time frame of: 23 months.
Primary	Percentage of Individuals Completing the Full Protocol	The other primary outcome will be the percentage of individuals that complete informed consent which complete the full protocol.	Outcomes will be cumulatively assessed from the time that the first participant completes informed consent through the time that the last participant completes the final follow-up visit. Estimated time frame of: 23 months.
Secondary	Change in Depression Severity	Secondary outcomes will include changes in depression severity (as measured on the Montgomery-Asberg Depression Rating Scale), which will be calculated as a change from baseline to 4-week followup. Montgomery Asberg Depression Rating Scale (MADRS; Montgomery, 1979). The MADRS is a clinician administered, 10-item questionnaire of depression severity. The total score ranges from 0-60, with scores of 0-6 considered normal (non-depressed), 7-19 indicative of mild depression, 20-34 indicative of moderate depression, and 35-60 indicative of severe depression. Individuals scoring 20 or higher on the MADRS will be included in the study. The MADRS evaluates the following symptoms of depression: 1) clinical appearance of sadness, 2) self-reported sadness, 3) inner tension, 4) reduced sleep, 5) reduced appetite, 6) concentration difficulties, 7) lassitude, 8) inability to feel, 9) pessimistic thought process, and 10) thoughts of suicide.	Baseline through 4 week follow-up.